ACADIA CFO Mark Schneyer Exercises Options, Sells 20,141 Shares

What Happened
Mark C. Schneyer, Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), exercised stock options and sold the resulting shares on Aug 5–6, 2026. He exercised a total of 20,141 option shares (5,849 on Aug 5 and 14,292 on Aug 6) at an exercise price of $17.84, costing about $359,315 to exercise. He sold all 20,141 shares in open-market transactions at prices around $29.00–$29.34 for aggregate gross proceeds of approximately $587,242. The exercises were effectively followed by immediate sales (a cashless outcome), so the exercises did not increase his net shareholdings from the option conversion.

Key Details

• Transaction dates: Aug 5–6, 2026; Form 4 filed Aug 7, 2026 (filed within the normal two-business-day window).
• Exercise details: 20,141 shares exercised at $17.84 (total exercise cost ≈ $359,315).
• Sale details: 20,141 shares sold in the open market for total proceeds ≈ $587,242; sale prices reported roughly $29.00 and $29.34 (some lots reported as a weighted average).
• Net effect: All exercised shares were sold, so no net gain in shares from these exercises. The filing does not state Schneyer’s total shares owned after these transactions.
• Footnotes of note:
  • F2: Sales were made pursuant to a Rule 10b5-1 trading plan adopted May 19, 2025.
  • F3: Some reported sale prices are weighted averages for multiple execution prices (ranges noted in the filing).
  • F1/F4: Filing notes an earlier ESPP purchase (1,683 shares on May 15, 2026) and the vesting schedule for the stock option (25% vested Mar 25, 2025; remainder vest monthly over 36 months).

Context
These entries reflect option exercises followed by immediate open-market sales (a common cashless exercise pattern), and the sales were executed under a pre-established 10b5-1 plan. That means the timing of the sales was likely predetermined and should not be read as an on-the-spot sentiment indicator. The filing is transactional (insider reporting) and factual; it does not provide management rationale.